Physician profile
Pius Efobi
NPI 1306538707
$5,027.99
in general payments reported to CMS, 2019-2025
15 companies · $2,324 in 2025
The $2,324 reported for 2025 was more than what 94% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $192 · 2024: $2,512 · 2025: $2,324.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,917 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,916.50 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,253.76 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $754.70 | 2024-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $686.07 | 2024-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $587.28 | 2023-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Alkermes, INC. | $496.08 | 2024-2025 | Lybalvi, Aristada, Vivitrol |
| Janssen Pharmaceuticals, INC | $377.96 | 2024-2025 | Spravato, Invega Sustenna |
| Neurocrine Biosciences, INC. | $275.63 | 2024-2025 | Ingrezza |
| Braeburn INC. | $227.86 | 2024 | Brixadi |
| Axsome Therapeutics, INC. | $104.80 | 2024-2025 | Auvelity, Sunosi |
| Vanda Pharmaceuticals INC. | $65.73 | 2025 | Fanapt |
| E.R. Squibb & Sons, L.L.C. | $60.50 | 2025 | Cobenfy |
| Indivior INC. | $54.05 | 2024-2025 | Sublocade, Perseris |
| Tempus Ai, INC | $52.62 | 2024 | |
| Ironshore Pharmaceuticals INC. | $15.48 | 2024 | |
| Eisai INC. | $15.47 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pius Efobi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.